The impact of Bcl-3 expression and signaling in cancer
Sammanfattning: Bcl-3 is a proto-oncogene and belongs to the inhibitor of ?B (I?B) family and is known to be upregulated in numerous cancers. Bcl-3 can initiate transcription of different genes involved in cell survival and cell growth. Cell proliferation is achieved through binding of Bcl-3 to cyclin D1 promoter and facilitates the rapid transition from G1 to S phase. The aim of this thesis was to investigate the role of Bcl-3 in different types of cancers including prostate, colon, and melanoma as well as to identify a selective inhibitor against Bcl-3 protein. In prostate cancer (PC) we observed the upregulation of Bcl-3 in cancer cells adjacent to infiltration of inflammatory cells. More precisely in PC cell lines we found out that Bcl-3 was upregulated with the stimulation of IL-6 through STAT3 signaling pathway. Silencing of Bcl-3 in PC cell lines sensitize these cells against anticancer drugs treatment and formed small tumors in vivo compared to control treated cells. In colon cancer we found that Bcl-3 localization differed comparing non-cancerous with cancer cells. Bcl-3 was mainly localized in cytoplasm of cancer tissue compared to nucleus in normal colon tissue. Out of six colon cancer lines three of them showed highest expression of Bcl-3. Cell fractionation analysis of these cell lines reiterated that majority of Bcl-3 protein was localized in the cytoplasm. Furthermore, the cytoplasmic localization of Bcl-3 in cancer cells correlated positively with proliferation marker Ki67 but not with the apoptotic marker cleaved caspase 3. Results obtained from this study suggest that cytoplasmic presence of Bcl-3 could be used as a diagnostic marker in certain stages of colon cancer. Since so far no inhibitors against Bcl-3 exist, we decided to identify a specific inhibitor against Bcl-3 protein. For this purpose we screened among 1368 synthetic compounds and could identify a specific Bcl-3 inhibitor. Treatment of melanoma cells with Bcl-3 inhibitor or its related derivate reduced the proliferation and arrested cells at G1/S phase of the cell cycle. Results from this study suggest that our newly identified Bcl-3 inhibitor can be used as anticancer drug to reduce the proliferation in melanoma.
Denna avhandling är EVENTUELLT nedladdningsbar som PDF. Kolla denna länk för att se om den går att ladda ner.